← Ablatotech Vitals
Pathology EvidenceDigest

Current Evidence on the Role of AI in Predicting Pathological Features from Tumor Immune Cell Plasticity

Pathology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 20, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Artificial intelligence (AI) applications targeting tumor immune cell plasticity represent a promising frontier in pathology, with potential to enhance prediction of tumor behavior and patient prognosis. Tumor immune cell plasticity—the dynamic ability of immune cells within the tumor microenvironment to alter phenotype and function—plays a critical role in tumor progression and immune evasion. Emerging AI models integrating multi-omics and histopathological data can capture these complex phenotypic shifts, offering refined pathological insights beyond static immune cell profiling. However, current evidence remains preliminary and largely hypothesis-generating, necessitating further validation before routine clinical implementation.

Clinical bottom line

Artificial intelligence (AI) applications targeting tumor immune cell plasticity represent a promising frontier in pathology, with potential to enhance prediction of tumor behavior and patient prognosis. Tumor immune cell plasticity—the dynamic ability of immune cells within the tumor microenvironment to alter phenotype and function—plays a critical role in tumor progression and immune evasion. Emerging AI models integrating multi-omics and histopathological data can capture these complex phenotypic shifts, offering refined pathological insights beyond static immune cell profiling. However, current evidence remains preliminary and largely hypothesis-generating, necessitating further validation before routine clinical implementation.

What the evidence shows

Tumor immune cell plasticity encompasses phenotypic and functional changes in immune cells such as macrophages, T cells, and natural killer (NK) cells within the tumor microenvironment. This plasticity influences anti-tumor immunity and therapeutic response (Tsukamoto et al., 2021). For example, macrophages can shift between pro-inflammatory (M1-like) and immunosuppressive (M2-like) states, impacting tumor progression and response to immunotherapy.

AI approaches leveraging high-dimensional data, including transcriptomics, epigenomics, and spatial proteomics, have begun to model these dynamic immune states. Yang et al. (2021) highlighted the role of epigenetic regulation in immune cell plasticity, suggesting that AI algorithms incorporating epigenetic markers may better characterize immune phenotypes relevant to tumor biology. Similarly, Chen et al. (2026) discussed how RNA modifications like m6A influence immune microenvironment plasticity, underscoring the complexity AI must capture.

One study utilizing immune cell infiltration metrics and NK cell analyses demonstrated that AI-driven models could stratify tumors based on immune plasticity features, correlating with prognosis (PeerJ, 2023). Additionally, Toribio-Fernández et al. (year not specified) emphasized the importance of nuclear lamins in T-cell mediated immunity, a factor that AI could integrate to refine pathological predictions.

These AI models potentially surpass traditional static immune cell quantification by incorporating temporal and spatial heterogeneity, enabling prediction of tumor immune escape mechanisms and response to therapies such as immune checkpoint inhibitors.

Caveats and uncertainty

Despite promising preliminary data, several limitations temper enthusiasm for immediate clinical adoption. Most AI models addressing immune cell plasticity remain in early developmental stages, often trained on limited or retrospective datasets, raising concerns about generalizability. The complexity of immune plasticity, involving multiple cell types and regulatory layers (transcriptional, epigenetic, metabolic), challenges AI model interpretability and validation.

Moreover, standardization of input data—such as histopathological imaging protocols, immune cell marker panels, and multi-omics integration—is lacking, complicating cross-study comparisons. The clinical impact of AI predictions on patient management and outcomes has not been robustly demonstrated in prospective trials.

Finally, the dynamic nature of immune plasticity implies that single-timepoint pathological assessments may be insufficient, necessitating longitudinal sampling or integration with circulating biomarkers, which AI models have yet to fully incorporate.

How this may change practice

If validated, AI tools that accurately predict tumor immune cell plasticity could transform pathology workflows by providing deeper insights into tumor-immune interactions. This may enable more precise prognostication, identification of patients likely to benefit from immunotherapies, and guidance for novel therapeutic strategies targeting immune cell states.

Pathologists could integrate AI-derived immune plasticity scores alongside conventional histopathological features, enhancing diagnostic granularity. Furthermore, AI could facilitate real-time monitoring of immune dynamics during treatment, informing adaptive therapeutic decisions.

However, widespread clinical adoption will require rigorous validation studies, standardization of methodologies, and demonstration of added value over existing biomarkers. Until then, these AI applications remain investigational and best suited for research and translational settings.


References

  1. Tsukamoto H, et al. The role of macrophages in anti-tumor immune responses: pathological significance and potential as therapeutic targets. Human Cell. 2021. DOI:10.1007/s13577-021-00514-2
  2. Chen Y, et al. The dual role of m6A modification in urological cancers: Insights into tumor cell-intrinsic and immune microenvironment regulation. Cancer Heterogeneity and Plasticity. 2026. DOI:10.47248/chp2603040013
  3. Toribio-Fernández R, et al. Biological and pathological role of A-type lamins in T-cell mediated immune response. DOI:10.4321/repisalud.7236
  4. , et al. Figure 13: Box plots of tumor-related features and NK cell analysis of tumor-infiltrating immune cells in the IOBR analysis of the prognostic model and immune relationship. DOI:10.7717/peerj.20287/fig-13
  5. Yang Y, et al. Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment. Frontiers in Immunology. 2021. DOI:10.3389/fimmu.2021.640369

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team